drugset
drugset / Trial / NCT02049515

A Phase 3 Extension Study of Duvelisib and Ofatumumab in Participants With CLL/SLL Previously Enrolled in Study IPI-145-07

NCT02049515 ↗

Phase 3 Completed 99 enrolled SecuraBio
Non-randomizedParallel-groupOpen-labelTreatment

Summary

A Phase 3 (extension) clinical trial to examine the efficacy of IPI-145 (duvelisib) monotherapy or ofatumumab monotherapy in participants with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who experienced disease progression after treatment with IPI-145 or ofatumumab in study IPI-145-07 (NCT02004522).

Timeline

Start
2013-12
Primary completion
2020-06-12
Completion
2020-06-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Duvelisib Small molecule 25 mg Oral
Comparator Ofatumumab Monoclonal antibody 2000 mg Intravenous

Indications

chronic lymphocytic leukemia/small lymphocytic lymphoma